Protara Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Protara Therapeutics, Inc. (TARA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 5.96 thousand shares for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2025-05-08
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 5.96K shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2019-12-31 was -2.53M shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2019-09-30 was 1.09M shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2018-12-31 was 0.00 shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 302.14K shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2019 was 80.43K shares, a 3.60% decline from fiscal 2018.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2018 was 83.43K shares, a 175.61% increase from fiscal 2017.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2017 was 30.27K shares, a 56.18% decline from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-03-31 | 5.96K shares 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 302.14K shares 10-K · filed 2025-03-05 | |||
| 2019-12-31 | -2.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | -1.43M shares derived: sum of 2 quarters · filed 2020-03-20 | 80.43K shares 10-K · filed 2020-03-20 | |
| 2019-09-30 | 1.09M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | 2.61M shares 10-Q · filed 2019-10-31 | ||
| 2019-06-30 | 1.51M shares 10-Q · filed 2019-08-07 | |||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | 0.00 shares derived: sum of 2 quarters · filed 2019-03-13 | 0.00 shares derived: sum of 3 quarters · filed 2019-03-13 | 83.43K shares 10-K · filed 2019-03-13 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | 0.00 shares derived: sum of 2 quarters · filed 2018-11-07 | 83.43K shares 10-Q · filed 2018-11-07 | 83.43K shares derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | 83.43K shares 10-Q · filed 2018-08-07 | 83.43K shares derived: sum of 3 quarters · filed 2018-08-07 | 99.02K shares derived: sum of 4 quarters · filed 2018-08-07 |
| 2018-03-31 | 83.43K shares 10-Q · filed 2018-05-09 | 83.43K shares derived: sum of 2 quarters · filed 2018-05-09 | 99.02K shares derived: sum of 3 quarters · filed 2018-05-09 | |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | 15.59K shares derived: sum of 2 quarters · filed 2018-03-14 | 30.27K shares 10-K · filed 2018-03-14 | |
| 2017-09-30 | 15.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 30.27K shares 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | 14.69K shares 10-Q · filed 2017-08-07 | |||
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | 62.00K shares derived: sum of 2 quarters · filed 2017-03-16 | 69.09K shares 10-K · filed 2017-03-16 | |
| 2016-09-30 | 62.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | 69.09K shares 10-Q · filed 2016-11-07 | ||
| 2016-06-30 | 7.09K shares 10-Q · filed 2016-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |